Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

RedHill Biopharma Announced New Publication Of Data Showing That Triple Antimicrobial Therapy With RHB-104 Plus Standard Of Care, Targeting Mycobacterium Avium Subspecies Paratuberculosis, Is 64% More Effective Than SoC Alone In Crohn's Disease

Author: Benzinga Newsdesk | August 01, 2024 07:43am

Posted In: RDHL

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist